person · Reporting owner

FRIEDMAN PAUL A

Disclosed activity across 5 companies

Tapewire entity: 39620
SEC CIK: 0001236927

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Dare Bioscience, Inc.CERU · Entity 7799	Director	April 03, 2017	April 05, 2017
INCYTE CORPINCY · Entity 3182	Director	May 26, 2020	May 28, 2020
MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441	Director	January 09, 2026	January 13, 2026
Prelude Therapeutics IncPRLD · Entity 5561	Director	June 09, 2026	June 10, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Dare Bioscience, Inc.

Report date April 03, 2017 · Filed April 05, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	18,819	Reported balance After 2017-04-03 transaction · row 1 1 source row Row 1 · 2017-04-03 · Grant · Acquired 10,273 · Balance 18,819 F1: Consists of shares of common stock issued in lieu of cash retainers for board and committee service in accordance with an election of the reporting person under the company's non-employee director compensation program. The number of shares is equal to the amount of the cash retainers that would otherwise have been payable to the reporting person for the first fiscal quarter of 2017 divided by $0.73, the closing price of the company's common stock on the NASDAQ Global Market on April 3, 2017.

Filing footnotes · ownership attribution and instrument terms

F1: Consists of shares of common stock issued in lieu of cash retainers for board and committee service in accordance with an election of the reporting person under the company's non-employee director compensation program. The number of shares is equal to the amount of the cash retainers that would otherwise have been payable to the reporting person for the first fiscal quarter of 2017 divided by $0.73, the closing price of the company's common stock on the NASDAQ Global Market on April 3, 2017.

INCYTE CORP

Report date May 26, 2020 · Filed May 28, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	256,813	Reported balance After 2020-05-26 transaction · row 1 1 source row Row 1 · 2020-05-26 · Grant · Acquired 1,282 · Balance 256,813 F1: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $98.68 · Expires 2030-05-25	Direct	10,514	Reported balance After 2020-05-26 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-05-26 · Grant · Acquired 10,514 · Balance 10,514 F3: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).
Common StockSEC Table I · non-derivative	IndirectBy Grat	15,000	Reported balance Holding disclosure · report date 2020-05-26 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 15,000 F2: Shares were previously reported as directly beneficially owned but were contributed to a grantor retained annuity trust (GRAT) on April 3, 2019.

Filing footnotes · ownership attribution and instrument terms

F1: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2: Shares were previously reported as directly beneficially owned but were contributed to a grantor retained annuity trust (GRAT) on April 3, 2019.

F3: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).

MADRIGAL PHARMACEUTICALS, INC.

Report date January 09, 2026 · Filed January 13, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	187,164	Ending reported balance After 2026-01-09 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-01-09 · Exercise / conversion · Acquired 280 · Balance 187,444 Row 2 · 2026-01-09 · Sale · Disposed 280 · Balance 187,164 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $551.24 to $551.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.80 · Expires 2027-03-02	Direct	0	Reported balance After 2026-01-09 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-01-09 · Exercise / conversion · Disposed 280 · Balance 0 F4: The shares underlying this stock option are fully vested and exercisable.
Common StockSEC Table I · non-derivative	IndirectBy SQN LLC	655,540	Reported balance Holding disclosure · report date 2026-01-09 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 655,540 F3: The Reporting Person and his spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $551.24 to $551.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The Reporting Person and his spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F4: The shares underlying this stock option are fully vested and exercisable.

Prelude Therapeutics Inc

Report date June 09, 2026 · Filed June 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.94 · Expires 2036-06-08	Direct	38,000	Reported balance After 2026-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-09 · Grant · Acquired 38,000 · Balance 38,000 F1: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ALEXION PHARMACEUTICALS, INC.

Report date July 21, 2021 · Filed July 23, 2021

Section 16 reporting ended · disclosed 2021-07-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $.0001 per shareSEC Table I · non-derivative	Direct	0	Reported balance After 2021-07-21 transaction · row 1 1 source row Row 1 · 2021-07-21 · Disposition to issuer · Disposed 12,840 · Balance 0 F1: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). Upon the First Effective Time, 2,495 restricted stock units were fully vested and cancelled and converted into the right to receive the Merger Consideration with respect to each share of Alexion common stock subject to such restricted stock units.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). Upon the First Effective Time, 2,495 restricted stock units were fully vested and cancelled and converted into the right to receive the Merger Consideration with respect to each share of Alexion common stock subject to such restricted stock units.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 09, 2026 Filed Jun 10, 2026 20:12 UTC	Prelude Therapeutics Inc PRLD · Entity 5561	GrantDirector Stock Option (Right to Buy) · Derivative	38,000	$0.00 Strike: $3.94	$0.00	Disclosure SEC source: 0001236927-26-000003 · primarydocument.xml · derivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2036-06-08 F1 · derivative.exercise_date: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:47 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	Exercise / conversionStock Option (Right to Buy) · Derivative	280	$0.00 Strike: $15.80	$0.00	Disclosure SEC source: 0001628280-26-001981 · wk-form4_1768340834.xml · derivative · entry 4 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 280 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:47 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	280	$551.24	$154,347.59	Disclosure SEC source: 0001628280-26-001981 · wk-form4_1768340834.xml · nonDerivative · entry 2 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,164 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $551.24 to $551.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:47 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	Exercise / conversionCommon Stock	280	$15.80	$4,424.00	Disclosure SEC source: 0001628280-26-001981 · wk-form4_1768340834.xml · nonDerivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:43 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	Exercise / conversionStock Option (Right to Buy) · Derivative	24,520	$0.00 Strike: $15.80	$0.00	Disclosure SEC source: 0001628280-26-001976 · wk-form4_1768340585.xml · derivative · entry 31 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 280 Underlying: Common Stock · 24,520 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F29 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:43 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	40	$545.79	$21,831.60	Disclosure SEC source: 0001628280-26-001976 · wk-form4_1768340585.xml · nonDerivative · entry 29 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,164 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:43 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	600	$540.36	$324,214.80	Disclosure SEC source: 0001628280-26-001976 · wk-form4_1768340585.xml · nonDerivative · entry 28 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,204 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F27 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $540.25 to $540.38, inclusive. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:43 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	480	$539.23	$258,831.22	Disclosure SEC source: 0001628280-26-001976 · wk-form4_1768340585.xml · nonDerivative · entry 27 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,804 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F26 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $539.00 to $539.42, inclusive. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:43 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	80	$537.85	$43,027.60	Disclosure SEC source: 0001628280-26-001976 · wk-form4_1768340585.xml · nonDerivative · entry 26 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 188,284 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F25 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $537.83 to $537.86, inclusive. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:43 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	487	$536.88	$261,459.00	Disclosure SEC source: 0001628280-26-001976 · wk-form4_1768340585.xml · nonDerivative · entry 25 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 188,364 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F24 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $536.64 to $537.11, inclusive. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:43 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	473	$536.02	$253,537.74	Disclosure SEC source: 0001628280-26-001976 · wk-form4_1768340585.xml · nonDerivative · entry 24 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 188,851 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F23 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $535.62 to $536.57, inclusive. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:43 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	148	$535.29	$79,222.71	Disclosure SEC source: 0001628280-26-001976 · wk-form4_1768340585.xml · nonDerivative · entry 23 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 189,324 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F22 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $534.60 to $535.57, inclusive. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:43 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	332	$534.16	$177,342.38	Disclosure SEC source: 0001628280-26-001976 · wk-form4_1768340585.xml · nonDerivative · entry 22 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 189,472 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F21 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $533.60 to $534.54, inclusive. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:43 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	80	$532.50	$42,600.00	Disclosure SEC source: 0001628280-26-001976 · wk-form4_1768340585.xml · nonDerivative · entry 21 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 189,804 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:43 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	280	$530.69	$148,592.39	Disclosure SEC source: 0001628280-26-001976 · wk-form4_1768340585.xml · nonDerivative · entry 20 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 189,884 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F20 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $530.63 to $531.03, inclusive. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:43 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	166	$529.76	$87,940.56	Disclosure SEC source: 0001628280-26-001976 · wk-form4_1768340585.xml · nonDerivative · entry 19 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 190,164 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F19 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $529.56 to $530.12, inclusive. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:43 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	691	$529.17	$365,653.29	Disclosure SEC source: 0001628280-26-001976 · wk-form4_1768340585.xml · nonDerivative · entry 18 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 190,330 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F18 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $528.56 to $529.52, inclusive. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:43 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	575	$528.18	$303,702.18	Disclosure SEC source: 0001628280-26-001976 · wk-form4_1768340585.xml · nonDerivative · entry 17 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 191,021 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $527.56 to $528.53, inclusive. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:43 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	1,560	$526.97	$822,070.86	Disclosure SEC source: 0001628280-26-001976 · wk-form4_1768340585.xml · nonDerivative · entry 16 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 191,596 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $526.56 to $527.51, inclusive. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:43 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	1,066	$526.00	$560,716.53	Disclosure SEC source: 0001628280-26-001976 · wk-form4_1768340585.xml · nonDerivative · entry 15 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 193,156 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $525.55 to $526.50, inclusive. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:43 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	2,432	$525.05	$1,276,915.52	Disclosure SEC source: 0001628280-26-001976 · wk-form4_1768340585.xml · nonDerivative · entry 14 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 194,222 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $524.51 to $525.49, inclusive. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:43 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	1,199	$524.10	$628,394.22	Disclosure SEC source: 0001628280-26-001976 · wk-form4_1768340585.xml · nonDerivative · entry 13 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 196,654 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $523.51 to $524.48, inclusive. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:43 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	970	$523.00	$507,307.28	Disclosure SEC source: 0001628280-26-001976 · wk-form4_1768340585.xml · nonDerivative · entry 12 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 197,853 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $522.49 to $523.46, inclusive. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:43 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	840	$521.98	$438,461.44	Disclosure SEC source: 0001628280-26-001976 · wk-form4_1768340585.xml · nonDerivative · entry 11 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 198,823 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $521.49 to $522.40, inclusive. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:43 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	681	$521.03	$354,823.27	Disclosure SEC source: 0001628280-26-001976 · wk-form4_1768340585.xml · nonDerivative · entry 10 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 199,663 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $520.48 to $521.45, inclusive. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:43 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	846	$519.88	$439,821.69	Disclosure SEC source: 0001628280-26-001976 · wk-form4_1768340585.xml · nonDerivative · entry 9 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 200,344 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $519.45 to $520.42, inclusive. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:43 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	1,363	$518.68	$706,965.88	Disclosure SEC source: 0001628280-26-001976 · wk-form4_1768340585.xml · nonDerivative · entry 8 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 201,190 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $518.38 to $519.37, inclusive. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:43 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	2,450	$517.86	$1,268,754.80	Disclosure SEC source: 0001628280-26-001976 · wk-form4_1768340585.xml · nonDerivative · entry 7 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 202,553 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $517.36 to $518.35, inclusive. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:43 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	766	$516.84	$395,896.07	Disclosure SEC source: 0001628280-26-001976 · wk-form4_1768340585.xml · nonDerivative · entry 6 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,003 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $516.34 to $517.28, inclusive. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:43 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	1,996	$515.81	$1,029,561.35	Disclosure SEC source: 0001628280-26-001976 · wk-form4_1768340585.xml · nonDerivative · entry 5 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,769 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $515.29 to $516.21, inclusive. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:43 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	1,345	$514.68	$692,245.95	Disclosure SEC source: 0001628280-26-001976 · wk-form4_1768340585.xml · nonDerivative · entry 4 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 207,765 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $514.28 to $515.22, inclusive. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:43 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	1,094	$513.11	$561,340.04	Disclosure SEC source: 0001628280-26-001976 · wk-form4_1768340585.xml · nonDerivative · entry 3 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 209,110 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $512.77 to $513.60, inclusive. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:43 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	1,480	$511.98	$757,726.55	Disclosure SEC source: 0001628280-26-001976 · wk-form4_1768340585.xml · nonDerivative · entry 2 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,204 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $511.71 to $512.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:43 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	Exercise / conversionCommon Stock	24,520	$15.80	$387,416.00	Disclosure SEC source: 0001628280-26-001976 · wk-form4_1768340585.xml · nonDerivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 211,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 10, 2025 Filed Dec 12, 2025 21:40 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	Exercise / conversionStock Option (Right to Buy) · Derivative	24,800	$0.00 Strike: $15.80	$0.00	Disclosure SEC source: 0001628280-25-056794 · wk-form4_1765575628.xml · derivative · entry 12 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,800 Underlying: Common Stock · 24,800 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document
December 10, 2025 Filed Dec 12, 2025 21:40 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	160	$555.39	$88,862.40	Disclosure SEC source: 0001628280-25-056794 · wk-form4_1765575628.xml · nonDerivative · entry 10 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,164 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. Read SEC document
December 10, 2025 Filed Dec 12, 2025 21:40 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	1,029	$555.00	$571,091.19	Disclosure SEC source: 0001628280-25-056794 · wk-form4_1765575628.xml · nonDerivative · entry 9 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,324 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $554.39 to $555.31, inclusive. Read SEC document
December 10, 2025 Filed Dec 12, 2025 21:40 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	5,001	$553.83	$2,769,728.33	Disclosure SEC source: 0001628280-25-056794 · wk-form4_1765575628.xml · nonDerivative · entry 8 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 188,353 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $553.28 to $554.27, inclusive. Read SEC document
December 10, 2025 Filed Dec 12, 2025 21:40 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	5,533	$552.74	$3,058,332.00	Disclosure SEC source: 0001628280-25-056794 · wk-form4_1765575628.xml · nonDerivative · entry 7 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 193,354 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $552.28 to $553.27, inclusive. Read SEC document
December 10, 2025 Filed Dec 12, 2025 21:40 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	7,193	$551.67	$3,968,128.50	Disclosure SEC source: 0001628280-25-056794 · wk-form4_1765575628.xml · nonDerivative · entry 6 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 198,887 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $551.28 to $552.26, inclusive. Read SEC document
December 10, 2025 Filed Dec 12, 2025 21:40 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	4,316	$550.93	$2,377,825.96	Disclosure SEC source: 0001628280-25-056794 · wk-form4_1765575628.xml · nonDerivative · entry 5 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 206,080 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $550.28 to $551.26, inclusive. Read SEC document
December 10, 2025 Filed Dec 12, 2025 21:40 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	409	$549.99	$224,944.72	Disclosure SEC source: 0001628280-25-056794 · wk-form4_1765575628.xml · nonDerivative · entry 4 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,396 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $549.27 to $550.23, inclusive. Read SEC document
December 10, 2025 Filed Dec 12, 2025 21:40 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	535	$548.51	$293,451.08	Disclosure SEC source: 0001628280-25-056794 · wk-form4_1765575628.xml · nonDerivative · entry 3 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,805 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $548.17 to $549.08, inclusive. Read SEC document
December 10, 2025 Filed Dec 12, 2025 21:40 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	624	$547.75	$341,793.63	Disclosure SEC source: 0001628280-25-056794 · wk-form4_1765575628.xml · nonDerivative · entry 2 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 211,340 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $547.17 to $548.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Read SEC document
December 10, 2025 Filed Dec 12, 2025 21:40 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	Exercise / conversionCommon Stock	24,800	$15.80	$391,840.00	Disclosure SEC source: 0001628280-25-056794 · wk-form4_1765575628.xml · nonDerivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 211,964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 13, 2025 Filed Aug 13, 2025 22:18 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	Exercise / conversionStock Option (Right to Buy) · Derivative	129,172	$0.00 Strike: $9.45	$0.00	Disclosure SEC source: 0001236927-25-000007 · wk-form4_1755123534.xml · derivative · entry 20 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 129,172 shares Expires 2026-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F20 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document
August 13, 2025 Filed Aug 13, 2025 22:18 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	4,155	$374.38	$1,555,563.44	Disclosure SEC source: 0001236927-25-000007 · wk-form4_1755123534.xml · nonDerivative · entry 18 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,164 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F18 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $373.94 to $374.60, inclusive. Read SEC document
August 13, 2025 Filed Aug 13, 2025 22:18 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	24,166	$373.35	$9,022,330.18	Disclosure SEC source: 0001236927-25-000007 · wk-form4_1755123534.xml · nonDerivative · entry 17 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 191,319 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $372.92 to $373.90, inclusive. Read SEC document
August 13, 2025 Filed Aug 13, 2025 22:18 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	28,976	$372.39	$10,790,485.65	Disclosure SEC source: 0001236927-25-000007 · wk-form4_1755123534.xml · nonDerivative · entry 16 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 215,485 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $371.92 to $372.91, inclusive. Read SEC document
August 13, 2025 Filed Aug 13, 2025 22:18 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	22,710	$371.53	$8,437,339.56	Disclosure SEC source: 0001236927-25-000007 · wk-form4_1755123534.xml · nonDerivative · entry 15 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 244,461 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $370.92 to $371.91, inclusive. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.